How does JCARE's PE Ratio compare to its peers?

JCARE is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (22.4x).

How does JCARE's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

JCARE is good value based on its Price-To-Earnings Ratio (14.4x) compared to the European Pharmaceuticals industry average (19.3x).

What is JCARE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JCARE is good value based on its Price-To-Earnings Ratio (14.4x) compared to the estimated Fair Price-To-Earnings Ratio (18.3x).

What is the Fair Price of JCARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

JCARE ($8) is trading below our estimate of [[fair value]] ($34.37)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

JCARE Stock Overview

Joincare Pharmaceutical Group Industry Co.,Ltd. More details

JCARE fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	3/6
Financial Health	5/6
Dividends	4/6

Rewards

Trading at 76.7% below our estimate of its fair value

Earnings are forecast to grow 11.78% per year

Earnings have grown 10.5% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for JCARE from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Joincare Pharmaceutical Group Industry Co.,Ltd. Competitors

Dottikon ES Holding

SWX:DESN

CHF 3.0b

Cosmo Pharmaceuticals

SWX:COPN

CHF 957.9m

Novartis

SWX:NOVN

CHF 173.4b

Roche Holding

SWX:ROG

CHF 198.6b

Price History & Performance

Summary of share price highs, lows and changes for Joincare Pharmaceutical Group IndustryLtd
Historical stock prices
Current Share Price	CN¥8.00
52 Week High	CN¥0
52 Week Low	CN¥0
Beta	0.43
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-44.06%

Recent updates

Shareholder Returns

	JCARE	CH Pharmaceuticals	CH Market
7D	0%	-2.2%	-2.4%
1Y	0%	2.7%	0.7%

Return vs Industry: JCARE underperformed the Swiss Pharmaceuticals industry which returned 2.7% over the past year.

Return vs Market: JCARE matched the Swiss Market which returned 0.7% over the past year.

Price Volatility

Is JCARE's price volatile compared to industry and market?
JCARE volatility
JCARE Average Weekly Movement	0%
Pharmaceuticals Industry Average Movement	3.1%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine JCARE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1992	14,365	Xiong Yu	www.joincare.com

Joincare Pharmaceutical Group Industry Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals and health care products primarily in China. The company offers chemical preparation for drugs, including digestive tract, cardiovascular and cerebrovascular, antimicrobial, anti-tumor, assisted reproductive, neurological therapeutic, OCT, and other drugs; and traditional Chinese drug preparation production, which includes anti-tumor and cold products.

Joincare Pharmaceutical Group Industry Co.,Ltd. Fundamentals Summary

How do Joincare Pharmaceutical Group IndustryLtd's earnings and revenue compare to its market cap?
JCARE fundamental statistics
Market cap	US$2.91b
Earnings (TTM)	US$201.57m
Revenue (TTM)	US$2.18b

14.4x

P/E Ratio

1.3x

P/S Ratio

Is JCARE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JCARE income statement (TTM)
Revenue	CN¥15.89b
Cost of Revenue	CN¥6.16b
Gross Profit	CN¥9.73b
Other Expenses	CN¥8.26b
Earnings	CN¥1.47b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.78
Gross Margin	61.21%
Net Profit Margin	9.25%
Debt/Equity Ratio	22.7%

How did JCARE perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

23%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 17:30
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Joincare Pharmaceutical Group Industry Co.,Ltd. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yanyin Zhu	China International Capital Corporation Limited
Ling Bo Tu	China Minzu Securities
Shitong Han	Citic Securities Co., Ltd.